At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 13 enrolled
Drug / intervention
Maltose (placebo) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Probiotics for Quality of Life in Autism Spectrum Disorders
In Brief
A Early Phase 1 clinical trial evaluating Maltose (placebo) and Visbiome Extra Strength for Autism Spectrum Disorders and Anxiety. Completed, enrolled 13 participants across 1 site.
Detailed Summary
A randomized pilot trial of a probiotic for quality of life in autism spectrum disorder (ASD), targeting gastrointestinal (GI) symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorders, Anxiety
CountriesUnited States
CollaboratorsAutism Treatment Network, Autism Speaks
Timeline
Early Ph 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedSep 2016
Primary CompletionDec 2017
TodayJul 2026
First PostedSep 16, 2016
Enrollment StartAug 1, 2016
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.8 years ago
Interventions
Maltose (placebo)drug
Maltose with a trace amount of silicon dioxide
Visbiome Extra Strengthdrug
It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety